Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?

Podobne zapisy

• Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis
  od: Choudhury, Rashikh, i wsp.
  Wydane: (2020)
• Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series
  od: Wang, Janice, i wsp.
  Wydane: (2020)
• Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: Scientific rationale and review
  od: Christopher D. Barrett, i wsp.
  Wydane: (2020-05-01)
• Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: Scientific rationale and review
  od: Barrett, Christopher D., i wsp.
  Wydane: (2020)
• Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series
  od: Barrett, Christopher D., i wsp.
  Wydane: (2020)